Revolutionary Medical Therapies and Innovative Cosmetic Solutions
Driven by the needs of patients. Fueled by data. Guided by compassion.
Our Purpose
At CB21 Pharma, we advance healthcare through scientific innovation. We use natural active pharmaceutical ingredients (APIs) to develop medical therapies and groundbreaking cosmetic solutions, focusing on non-psychotropic cannabinoids.
Our evidence-based approach ensures effective treatments and measurable results. Our research integrates sustainable practices and demonstrates our commitment to environmental responsibility.
Our Mission
We develop advanced medical treatments to establish new therapeutic standards. To address unmet medical needs, we harness the untapped therapeutic potential of non-psychotropic cannabinoids in combination with other compounds.
Our Vision
We intend to stand at the forefront of medical innovation by developing and commercializing advanced treatments for a variety of medical conditions. We exploit the therapeutic potential of non-psychotropic cannabinoids skillfully combined with other compounds to address less commonly targeted indications.
2018
Founding of CB21 Pharma
2020
Acquired EU GMP Part II certification for manufacturing API cannabidiol
2021
Acquired ISO 13485 certification and CE certification for two medical devices used in gynaecology and proctology (CANNEFF SUP and VAG SUP), a first in the European Union
2023
Extended EU GMP Part II certification for the manufacture of refined medical cannabis extracts
2024
Extended EU GMP Part II certification for the manufacture of Dronabinol (D9-THC)
Our Focus
Research and Development
The medical benefits of cannabinoids are often misunderstood, and their perceived benefits are sometimes overstated. Through our commitment to evidence-based medicine, we have identified specific conditions where cannabinoid therapy has demonstrated efficacy. Our research and clinical trials aim to advance treatment options in the following medical areas:
GYNAECOLOGY
UROLOGY
PROCTOLOGY
DENTISTRY
PSYCHIATRY
Why Phytocannabinoids
Phytocannabinoids demonstrate significant therapeutic potential through their pleiotropic effects and broad receptor interactions, extending beyond the endocannabinoid system. CBD and THC show promise in managing chronic pain, intractable nausea and vomiting, multiple sclerosis-related spasticity, and severe treatment-resistant epilepsy. CB21 Pharma focuses on prevalent conditions for which current treatments are limited.
What
We Do Best
Our comprehensive R&D process includes preclinical and clinical evaluations to ensure safety, efficacy, and correct dosages. We deliver validated products through close collaboration with our scientific board and Czech faculty hospitals.
Data is
the Missing Link
While knowledge about phytocannabinoids continues to grow, clinical evidence is vital for its widespread adoption. Products supported by robust data are crucial for market acceptance. At CB21 Pharma, we prioritize data-driven research to validate our products and build confidence in phytocannabinoids as therapeutic options.
CANNEFF®:
Advanced Cosmetic Solutions
In addition to our pharmaceutical efforts, we develop, manufacture and market CANNEFF®, a 21st-century clean-label brand that embodies the latest scientific advances in functional cosmetics. Combining cutting-edge research, potent natural ingredients and sophisticated design, CANNEFF® also sets new standards in the market. Our dedication to innovation, respect for natural resources, and the utilization of advanced dermatological and chemical expertise guarantee our products' effectiveness, safety, and purity.
Portfolio
Product
Pipeline
Porfolio
Two innovative suppository products are CE certified in the EU as medical devices for both vaginal and rectal use.
Clinical Trials
Ongoing for label extension.
Patent Protection
Pending in the EU, USA, CA, AU, BR, and GB.
Development
Full pipeline of other innovative products in preclinical and clinical development, including pilot phase and phase 2 clinical trials to evaluate efficacy and safety.
Team
Scientific
Board
CB21 Pharma's Scientific Board comprises distinguished experts who lead our research and development initiatives.
Prof. Jan Vacek, PhD
President of the Scientific Board, specializing in in vitro experiments, clinical trial design, and management. He is affiliated with the Department of Medical Chemistry and Biochemistry at the Faculty of Medicine and Dentistry, Palacký University Olomouc.
Prof. PharmDr. Petr Babula, PhD
Board member focusing on in vivo animal experiments, including toxicity, pharmacokinetics, and pharmacodynamics. He heads the Department of Physiology at the Faculty of Medicine, Masaryk University Brno.
Prof. MUDr. Luděk Fiala, PhD
Board member with expertise in gynaecology and sexology, serving at the First Faculty of Medicine, Charles University, Faculty of Medicine in Pilsen.
MUDr. Tomáš Páleníček, Ph.D.
Board member specializing in psychiatry, associated with the Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, and NIMH.
External
Board Members
Assoc. Prof. MUDr. Vladimír Študent, PhD
External board member specializing in urology, Head of the Urology Clinic at Olomouc University Hospital.
Gabriel Gonzalez, PhD
Specializes in in-vitro neurological experiments focusing on neurodegenerative disorders, affiliated with the Department of Neurology at University Hospital in Olomouc and the Department of Experimental Biology at Palacký University Olomouc.
Our Leadership
Jan Storch
CEO, Co-founder, Pharma R&D
Jan Storch graduated from the Czech University of Chemistry and Technology in Prague with a degree in organic chemistry. He completed his PhD at the Czech Academy of Sciences and is the head of the Department of Advanced Materials and Organic Synthesis. His fascination with chemical processes has led to significant scientific findings, including the development of an industrial method for isolating cannabidiol (CBD). This work resulted in the founding of CB21 Pharma Ltd. and its associated brand CANNEFF®, which he co-owns.
Lenka Průšová
COO, Co-founder, Cosmetics R&D & RA
Lenka Průšová graduated from the Czech University of Chemistry and Technology in Prague. Initially she focused on household chemistry, later on professional hair cosmetics, but it is skincare formulations that she has grown to love the most. She also gained experience abroad, especially in Canada. In 2014, after completing a programme at the Vrije Universiteit Brussels, she became the youngest cosmetics safety assessor in the Czech Republic. Together with Jan Storch, she launched the CANNEFF® brand. She is also a co-owner of CB21 Pharma Ltd, the only Czech pharmaceutical company with a GMP certificate for the production of API CBD and other phytocannabinoids.
Antonín Malík
Director QA & QC, Co-founder
Antonín Malík holds an MSc in biochemistry and pharmaceutical analytical methods. At CB21 Pharma, he is responsible for quality management systems for APIs and medical devices. His duties include implementing new procedures and process improvements, managing the product portfolio, conducting audits and inspections of manufacturers, and overseeing regulatory affairs for APIs and medical devices.
Partnering
Strategic and innovative partnerships
Strategic partnerships enable our global expansion. We seek collaborations in the following areas:
Out-licensing
Distribution
Product
co-development
R&D
collaborations
Strategic alliances
Why invest
in CB21 Pharma
Our research excellence, strategic focus, and commitment to quality make us a compelling investment opportunity. We are leaders in developing advanced medical and cosmetic solutions using non-psychotropic cannabinoids, addressing widespread conditions with limited therapeutic options.
At CB21 Pharma, our foundation is evidence-based research. Our R&D process encompasses comprehensive preclinical and clinical evaluations, ensuring treatment safety, efficacy, and precision. This systematic approach validates our therapies while establishing phytocannabinoids as credible therapeutic options.